185 related articles for article (PubMed ID: 36138076)
1. Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246.
Zhou X; Santos GS; Zhan Y; Oliveira MMS; Rezaei S; Singh M; Peuget S; Westerberg LS; Johnsen JI; Selivanova G
Br J Cancer; 2022 Nov; 127(11):2060-2071. PubMed ID: 36138076
[TBL] [Abstract][Full Text] [Related]
2. Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.
Xiao G; Lundine D; Annor GK; Canar J; Ellison V; Polotskaia A; Donabedian PL; Reiner T; Khramtsova GF; Olopade OI; Mazo A; Bargonetti J
Cancer Res; 2020 Feb; 80(3):394-405. PubMed ID: 31776133
[TBL] [Abstract][Full Text] [Related]
3. WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells.
Cuddihy AR; Jalali F; Coackley C; Bristow RG
Mol Cancer Ther; 2008 Apr; 7(4):980-92. PubMed ID: 18413811
[TBL] [Abstract][Full Text] [Related]
4. The C-terminus of Gain-of-Function Mutant p53 R273H Is Required for Association with PARP1 and Poly-ADP-Ribose.
Lundine D; Annor GK; Chavez V; Maimos S; Syed Z; Jiang S; Ellison V; Bargonetti J
Mol Cancer Res; 2022 Dec; 20(12):1799-1810. PubMed ID: 36074101
[TBL] [Abstract][Full Text] [Related]
5. A combination of p53-activating APR-246 and phosphatidylserine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenografts.
Liang Y; Mafuvadze B; Besch-Williford C; Hyder SM
Breast Cancer (Dove Med Press); 2018; 10():53-67. PubMed ID: 29606888
[TBL] [Abstract][Full Text] [Related]
6. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.
Liang Y; Besch-Williford C; Hyder SM
Int J Oncol; 2009 Nov; 35(5):1015-23. PubMed ID: 19787255
[TBL] [Abstract][Full Text] [Related]
7. APR-246 alone and in combination with a phosphatidylserine-targeting antibody inhibits lung metastasis of human triple-negative breast cancer cells in nude mice.
Liang Y; Besch-Williford C; Cook MT; Belenchia A; Brekken RA; Hyder SM
Breast Cancer (Dove Med Press); 2019; 11():249-259. PubMed ID: 31534364
[TBL] [Abstract][Full Text] [Related]
8. Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTp53.
Bristow RG; Peacock J; Jang A; Kim J; Hill RP; Benchimol S
Oncogene; 2003 May; 22(19):2960-6. PubMed ID: 12771947
[TBL] [Abstract][Full Text] [Related]
9. Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells.
Yi YW; Kang HJ; Kim HJ; Kong Y; Brown ML; Bae I
Oncotarget; 2013 Jul; 4(7):984-94. PubMed ID: 23846322
[TBL] [Abstract][Full Text] [Related]
10. Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells.
Liang Y; Besch-Williford C; Benakanakere I; Hyder SM
Int J Oncol; 2007 Oct; 31(4):777-84. PubMed ID: 17786308
[TBL] [Abstract][Full Text] [Related]
11. Mutant p53 suppresses innate immune signaling to promote tumorigenesis.
Ghosh M; Saha S; Bettke J; Nagar R; Parrales A; Iwakuma T; van der Velden AWM; Martinez LA
Cancer Cell; 2021 Apr; 39(4):494-508.e5. PubMed ID: 33545063
[TBL] [Abstract][Full Text] [Related]
12. P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy.
Said R; Hong DS; Warneke CL; Lee JJ; Wheler JJ; Janku F; Naing A; Falchook GS; Fu S; Piha-Paul S; Tsimberidou AM; Kurzrock R
Oncotarget; 2013 May; 4(5):705-14. PubMed ID: 23670029
[TBL] [Abstract][Full Text] [Related]
13. Impedimetric detection of mutant p53 biomarker-driven metastatic breast cancers under hyposmotic pressure.
Shi M; Shtraizent N; Polotskaia A; Bargonetti J; Matsui H
PLoS One; 2014; 9(6):e99351. PubMed ID: 24937470
[TBL] [Abstract][Full Text] [Related]
14. Role of Reactivating Mutant p53 Protein in Suppressing Growth and Metastasis of Triple-Negative Breast Cancer.
Berke TP; Slight SH; Hyder SM
Onco Targets Ther; 2022; 15():23-30. PubMed ID: 35035222
[TBL] [Abstract][Full Text] [Related]
15. Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities.
Kollareddy M; Dimitrova E; Vallabhaneni KC; Chan A; Le T; Chauhan KM; Carrero ZI; Ramakrishnan G; Watabe K; Haupt Y; Haupt S; Pochampally R; Boss GR; Romero DG; Radu CG; Martinez LA
Nat Commun; 2015 Jun; 6():7389. PubMed ID: 26067754
[TBL] [Abstract][Full Text] [Related]
16. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs.
Puca R; Nardinocchi L; Porru M; Simon AJ; Rechavi G; Leonetti C; Givol D; D'Orazi G
Cell Cycle; 2011 May; 10(10):1679-89. PubMed ID: 21508668
[TBL] [Abstract][Full Text] [Related]
17. A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells.
Garufi A; Trisciuoglio D; Porru M; Leonetti C; Stoppacciaro A; D'Orazi V; Avantaggiati M; Crispini A; Pucci D; D'Orazi G
J Exp Clin Cancer Res; 2013 Oct; 32(1):72. PubMed ID: 24220325
[TBL] [Abstract][Full Text] [Related]
18. Radioresistant MTp53-expressing rat embryo cell transformants exhibit increased DNA-dsb rejoining during exposure to ionizing radiation.
Bristow RG; Hu Q; Jang A; Chung S; Peacock J; Benchimol S; Hill R
Oncogene; 1998 Apr; 16(14):1789-802. PubMed ID: 9583677
[TBL] [Abstract][Full Text] [Related]
19. MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population.
Loo LWM; Gao C; Shvetsov YB; Okoro DR; Hernandez BY; Bargonetti J
Breast Cancer Res Treat; 2019 Feb; 174(1):257-269. PubMed ID: 30470976
[TBL] [Abstract][Full Text] [Related]
20. Mutant p53 oncogenic functions in cancer stem cells are regulated by WIP through YAP/TAZ.
Escoll M; Gargini R; Cuadrado A; Anton IM; Wandosell F
Oncogene; 2017 Jun; 36(25):3515-3527. PubMed ID: 28166194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
